Ombitasvir

SKU: orb1300018

Description

Ombitasvir

Research Area

Infectious Disease & Virology, Protein Biochemistry

Key Properties

• CAS Number: 1258226-87-7
• MW: 894.11
• Purity: 99.56%
• Formula: C₅₀H₆₇N₇O₈
• SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@]1(C(N)=O)c1ccc(cc1)[C@@H]1CC[C@H](N1c1ccc(cc1)C(C)(C)C)c1ccc(cc1)[C@]1(CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C)C(N)=O
• Target: HCV Protease
• Solubility: DMSO:50 mg/mL (55.92 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (2.24 mM)

Bioactivity

• Target IC50:
  HCVs 1-5:0.82 pM-19.3 pM(EC50) |HCV 6a:366 pM(EC50)
• In Vivo:
  Ombitasvir was evaluated in vivo in a 3-day monotherapy study in 12 HCV genotype 1-infected patients at 5, 25, 50, or 200 mg dosed once daily. All patients were HCV genotype 1a infected and were without preexisting resistant variants at baseline as determined by clonal sequencing. Decreases in HCV RNA up to 3.1 log10 IU/ml were observed. Resistance-associated variants at position 28, 30, or 93 in NS5A were detected in patient samples 48 hours after the first dose. Clonal sequencing analysis indicated that wild-type virus was largely suppressed by ombitasvir during 3-day monotherapy, and at doses higher than 5 mg, resistant variant M28V was also suppressed. Ombitasvir was well tolerated at all doses, and there were no serious or severe adverse events. These data support clinical development of ombitasvir in combination with inhibitors targeting HCV NS3/4A protease (ABT-450 with ritonavir) and HCV NS5B polymerase (ABT-333, dasabuvir) for the treatment of chronic HCV genotype 1 infection.
• Animal Research:
  The patients in the ombitasvir dose groups were enrolled sequentially, and within each group, patients were randomized (2:1) to either ombitasvir or placebo and treated under nonfasting conditions for 3 days while confined to the study site. The 200-mg dose group received a different formulation with higher bioavailability. Patients who received at least one dose of ombitasvir or placebo were provided the option to receive treatment with pegIFN/RBV for approximately 48 weeks once treatment with ombitasvir was completed. HCV RNA was measured using the Roche COBAS TaqMan HCV Test v2.0 real-time reverse transcriptase PCR assay (with a lower limit of quantification of 25 IU/ml and a lower limit of detection of 10 IU/ml). The virologic response was assessed as HCV RNA decrease from baseline in log10 IU/ml.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

ABT 267, ABT267, ABT-267, HCV, HCV Protease, HCV NS5A, HCVProtease, Hepatitis C virus, Inhibitor, Ombitasvir, inhibit

Compound Identifiers

PubChem CID

137699067